**Supplementary Table.**

**“A new, triglycyl peptide linker for antibody-drug conjugates (ADCs) with improved targeted killing of cancer cells”**

**Supplementary Table S1**: Amounts of catabolites generated upon treatment of cancer cells with CX and SMCC ADCs.

|  |  |  |  |
| --- | --- | --- | --- |
| Target,  **Supplementary Table S1**: Amounts of catabolites generated upon treatment of cancer cells with CX and SMCC ADCs.  *Cell line* *(antigen number per cell)* | Catabolites, pmol/millioncells (1 day) *a* | | |
| Cell | Medium | Total |  |  |
| CX SMCC | CX SMCC | CX SMCC |
| EGFR | | | |
| *HSC-2* *(106)* | 0.72 1.78 | 2.77 0.25 | 3.49 2.03 |
| *A-431*  *(9.7*x*105)* | 0.94 1.15 | 0.89 0.18 | 1.80 1.30 |  |  |
| *HCC827* *(6.7*x*105)* | 1.06 1.10 | 1.66 0.88 | 2.70 2.00 |  |  |
| EpCAM | | | |
| *Calu-3* *(3.6*x*105)* | 0.83 0.71 | 0.37 0.09 | 1.20 0.80 |
| *COLO 205* *(9.3*x*105)* | 0.77 1.03 | 2.40 1.60 | 3.17 2.63 |
| *HT-29* *(5-7*x*105)* | 0.91 1.02 | 0.67 0.38 | 1.60 1.40 |

*a*Cells were incubated with 2 g/mL (12 nM) ADC for ~2 h at 37 °C, then washed with medium to remove the unbound ADC, and further incubated in fresh medium for 1 day to allow processing. The catabolites in methanolic cell extract and medium were measured using maytansinoid-binding competition ELISA.